This document includes House Committee Amendments incorporated into the bill on Fri, Jan 22, 2021 at 10:25 AM by pflowers.
This document includes House Committee Amendments incorporated into the bill on Fri, Jan 22, 2021 at 2:49 PM by lfindlay.
This document includes Senate Committee Amendments incorporated into the bill on Wed, Feb 3, 2021 at 9:26 AM by lpoole.



Chief Sponsor: Raymond P. Ward

Senate Sponsor: Michael S. Kennedy


8     Committee Note:
9          The Health and Human Services Interim Committee recommended this bill.
10               Legislative Vote:     16 voting for     0 voting against     1 absent
11     General Description:
12          This bill modifies the Utah Controlled Substances Act.
13     Highlighted Provisions:
14          This bill:
15          ▸     removes an exception to the 7-day limit on prescriptions for certain controlled
16     substances after a surgery Ĥ→ [
.] ; and
16a          ▸ requires a practitioner to check the controlled substance database and consult with
16b     other practitioners when issuing a long-term prescription for an opiate or a benzodiazepine
16c     under certain circumstances. ←Ĥ
17     Money Appropriated in this Bill:
18          None
19     Other Special Clauses:
20          None
21     Utah Code Sections Affected:
22     AMENDS:
23          58-37-6, as last amended by Laws of Utah 2020, Chapter 81

25     Be it enacted by the Legislature of the state of Utah:
26          Section 1. Section 58-37-6 is amended to read:
27          58-37-6. License to manufacture, produce, distribute, dispense, administer, or

28     conduct research -- Issuance by division -- Denial, suspension, or revocation -- Records
29     required -- Prescriptions.
30          (1) (a) The division may adopt rules relating to the licensing and control of the
31     manufacture, distribution, production, prescription, administration, dispensing, conducting of
32     research with, and performing of laboratory analysis upon controlled substances within this
33     state.
34          (b) The division may assess reasonable fees to defray the cost of issuing original and
35     renewal licenses under this chapter pursuant to Section 63J-1-504.
36          (2) (a) (i) Every person who manufactures, produces, distributes, prescribes, dispenses,
37     administers, conducts research with, or performs laboratory analysis upon any controlled
38     substance in Schedules I through V within this state, or who proposes to engage in
39     manufacturing, producing, distributing, prescribing, dispensing, administering, conducting
40     research with, or performing laboratory analysis upon controlled substances included in
41     Schedules I through V within this state shall obtain a license issued by the division.
42          (ii) The division shall issue each license under this chapter in accordance with a
43     two-year renewal cycle established by rule. The division may by rule extend or shorten a
44     renewal period by as much as one year to stagger the renewal cycles it administers.
45          (b) Persons licensed to manufacture, produce, distribute, prescribe, dispense,
46     administer, conduct research with, or perform laboratory analysis upon controlled substances in
47     Schedules I through V within this state may possess, manufacture, produce, distribute,
48     prescribe, dispense, administer, conduct research with, or perform laboratory analysis upon
49     those substances to the extent authorized by their license and in conformity with this chapter.
50          (c) The following persons are not required to obtain a license and may lawfully possess
51     controlled substances included in Schedules II through V under this section:
52          (i) an agent or employee, except a sales representative, of any registered manufacturer,
53     distributor, or dispenser of any controlled substance, if the agent or employee is acting in the
54     usual course of the agent or employee's business or employment; however, nothing in this
55     subsection shall be interpreted to permit an agent, employee, sales representative, or detail man
56     to maintain an inventory of controlled substances separate from the location of the person's
57     employer's registered and licensed place of business;
58          (ii) a motor carrier or warehouseman, or an employee of a motor carrier or

59     warehouseman, who possesses a controlled substance in the usual course of the person's
60     business or employment; and
61          (iii) an ultimate user, or a person who possesses any controlled substance pursuant to a
62     lawful order of a practitioner.
63          (d) The division may enact rules waiving the license requirement for certain
64     manufacturers, producers, distributors, prescribers, dispensers, administrators, research
65     practitioners, or laboratories performing analysis if waiving the license requirement is
66     consistent with public health and safety.
67          (e) A separate license is required at each principal place of business or professional
68     practice where the applicant manufactures, produces, distributes, dispenses, conducts research
69     with, or performs laboratory analysis upon controlled substances.
70          (f) The division may enact rules providing for the inspection of a licensee or applicant's
71     establishment, and may inspect the establishment according to those rules.
72          (3) (a) (i) Upon proper application, the division shall license a qualified applicant to
73     manufacture, produce, distribute, conduct research with, or perform laboratory analysis upon
74     controlled substances included in Schedules I through V, unless it determines that issuance of a
75     license is inconsistent with the public interest.
76          (ii) The division may not issue a license to any person to prescribe, dispense, or
77     administer a Schedule I controlled substance except under Subsection (3)(a)(i).
78          (iii) In determining public interest under this Subsection (3)(a), the division shall
79     consider whether the applicant has:
80          (A) maintained effective controls against diversion of controlled substances and any
81     Schedule I or II substance compounded from any controlled substance into channels other than
82     legitimate medical, scientific, or industrial channels;
83          (B) complied with applicable state and local law;
84          (C) been convicted under federal or state laws relating to the manufacture, distribution,
85     or dispensing of substances;
86          (D) past experience in the manufacture of controlled dangerous substances;
87          (E) established effective controls against diversion; and
88          (F) complied with any other factors that the division establishes that promote the public
89     health and safety.

90          (b) Licenses granted under Subsection (3)(a) do not entitle a licensee to manufacture,
91     produce, distribute, conduct research with, or perform laboratory analysis upon controlled
92     substances in Schedule I other than those specified in the license.
93          (c) (i) Practitioners shall be licensed to administer, dispense, or conduct research with
94     substances in Schedules II through V if they are authorized to administer, dispense, or conduct
95     research under the laws of this state.
96          (ii) The division need not require a separate license for practitioners engaging in
97     research with nonnarcotic controlled substances in Schedules II through V where the licensee is
98     already licensed under this chapter in another capacity.
99          (iii) With respect to research involving narcotic substances in Schedules II through V,
100     or where the division by rule requires a separate license for research of nonnarcotic substances
101     in Schedules II through V, a practitioner shall apply to the division prior to conducting
102     research.
103          (iv) Licensing for purposes of bona fide research with controlled substances by a
104     practitioner considered qualified may be denied only on a ground specified in Subsection (4),
105     or upon evidence that the applicant will abuse or unlawfully transfer or fail to safeguard
106     adequately the practitioner's supply of substances against diversion from medical or scientific
107     use.
108          (v) Practitioners registered under federal law to conduct research in Schedule I
109     substances may conduct research in Schedule I substances within this state upon providing the
110     division with evidence of federal registration.
111          (d) Compliance by manufacturers, producers, and distributors with the provisions of
112     federal law respecting registration, excluding fees, entitles them to be licensed under this
113     chapter.
114          (e) The division shall initially license those persons who own or operate an
115     establishment engaged in the manufacture, production, distribution, dispensation, or
116     administration of controlled substances prior to April 3, 1980, and who are licensed by the
117     state.
118          (4) (a) Any license issued pursuant to Subsection (2) or (3) may be denied, suspended,
119     placed on probation, or revoked by the division upon finding that the applicant or licensee has:
120          (i) materially falsified any application filed or required pursuant to this chapter;

121          (ii) been convicted of an offense under this chapter or any law of the United States, or
122     any state, relating to any substance defined as a controlled substance;
123          (iii) been convicted of a felony under any other law of the United States or any state
124     within five years of the date of the issuance of the license;
125          (iv) had a federal registration or license denied, suspended, or revoked by competent
126     federal authority and is no longer authorized to manufacture, distribute, prescribe, or dispense
127     controlled substances;
128          (v) had the licensee's license suspended or revoked by competent authority of another
129     state for violation of laws or regulations comparable to those of this state relating to the
130     manufacture, distribution, or dispensing of controlled substances;
131          (vi) violated any division rule that reflects adversely on the licensee's reliability and
132     integrity with respect to controlled substances;
133          (vii) refused inspection of records required to be maintained under this chapter by a
134     person authorized to inspect them; or
135          (viii) prescribed, dispensed, administered, or injected an anabolic steroid for the
136     purpose of manipulating human hormonal structure so as to:
137          (A) increase muscle mass, strength, or weight without medical necessity and without a
138     written prescription by any practitioner in the course of the practitioner's professional practice;
139     or
140          (B) improve performance in any form of human exercise, sport, or game.
141          (b) The division may limit revocation or suspension of a license to a particular
142     controlled substance with respect to which grounds for revocation or suspension exist.
143          (c) (i) Proceedings to deny, revoke, or suspend a license shall be conducted pursuant to
144     this section and in accordance with the procedures set forth in Title 58, Chapter 1, Division of
145     Occupational and Professional Licensing Act, and conducted in conjunction with the
146     appropriate representative committee designated by the director of the department.
147          (ii) Nothing in this Subsection (4)(c) gives the Division of Occupational and
148     Professional Licensing exclusive authority in proceedings to deny, revoke, or suspend licenses,
149     except where the division is designated by law to perform those functions, or, when not
150     designated by law, is designated by the executive director of the Department of Commerce to
151     conduct the proceedings.

152          (d) (i) The division may suspend any license simultaneously with the institution of
153     proceedings under this section if it finds there is an imminent danger to the public health or
154     safety.
155          (ii) Suspension shall continue in effect until the conclusion of proceedings, including
156     judicial review, unless withdrawn by the division or dissolved by a court of competent
157     jurisdiction.
158          (e) (i) If a license is suspended or revoked under this Subsection (4), all controlled
159     substances owned or possessed by the licensee may be placed under seal in the discretion of the
160     division.
161          (ii) Disposition may not be made of substances under seal until the time for taking an
162     appeal has lapsed, or until all appeals have been concluded, unless a court, upon application,
163     orders the sale of perishable substances and the proceeds deposited with the court.
164          (iii) If a revocation order becomes final, all controlled substances shall be forfeited.
165          (f) The division shall notify promptly the Drug Enforcement Administration of all
166     orders suspending or revoking a license and all forfeitures of controlled substances.
167          (g) If an individual's Drug Enforcement Administration registration is denied, revoked,
168     surrendered, or suspended, the division shall immediately suspend the individual's controlled
169     substance license, which shall only be reinstated by the division upon reinstatement of the
170     federal registration, unless the division has taken further administrative action under
171     Subsection (4)(a)(iv), which would be grounds for the continued denial of the controlled
172     substance license.
173          (5) (a) A person licensed under Subsection (2) or (3) shall maintain records and
174     inventories in conformance with the record keeping and inventory requirements of federal and
175     state law and any additional rules issued by the division.
176          (b) (i) A physician, dentist, naturopathic physician, veterinarian, practitioner, or other
177     individual who is authorized to administer or professionally use a controlled substance shall
178     keep a record of the drugs received by the individual and a record of all drugs administered,
179     dispensed, or professionally used by the individual otherwise than by a prescription.
180          (ii) An individual using small quantities or solutions or other preparations of those
181     drugs for local application has complied with this Subsection (5)(b) if the individual keeps a
182     record of the quantity, character, and potency of those solutions or preparations purchased or

183     prepared by the individual, and of the dates when purchased or prepared.
184          (6) Controlled substances in Schedules I through V may be distributed only by a
185     licensee and pursuant to an order form prepared in compliance with division rules or a lawful
186     order under the rules and regulations of the United States.
187          (7) (a) An individual may not write or authorize a prescription for a controlled
188     substance unless the individual is:
189          (i) a practitioner authorized to prescribe drugs and medicine under the laws of this state
190     or under the laws of another state having similar standards; and
191          (ii) licensed under this chapter or under the laws of another state having similar
192     standards.
193          (b) An individual other than a pharmacist licensed under the laws of this state, or the
194     pharmacist's licensed intern, as required by Sections 58-17b-303 and 58-17b-304, may not
195     dispense a controlled substance.
196          (c) (i) A controlled substance may not be dispensed without the written prescription of
197     a practitioner, if the written prescription is required by the federal Controlled Substances Act.
198          (ii) That written prescription shall be made in accordance with Subsection (7)(a) and in
199     conformity with Subsection (7)(d).
200          (iii) In emergency situations, as defined by division rule, controlled substances may be
201     dispensed upon oral prescription of a practitioner, if reduced promptly to writing on forms
202     designated by the division and filed by the pharmacy.
203          (iv) Prescriptions reduced to writing by a pharmacist shall be in conformity with
204     Subsection (7)(d).
205          (d) Except for emergency situations designated by the division, an individual may not
206     issue, fill, compound, or dispense a prescription for a controlled substance unless the
207     prescription is signed by the prescriber in ink or indelible pencil or is signed with an electronic
208     signature of the prescriber as authorized by division rule, and contains the following
209     information:
210          (i) the name, address, and registry number of the prescriber;
211          (ii) the name, address, and age of the person to whom or for whom the prescription is
212     issued;
213          (iii) the date of issuance of the prescription; and

214          (iv) the name, quantity, and specific directions for use by the ultimate user of the
215     controlled substance.
216          (e) A prescription may not be written, issued, filled, or dispensed for a Schedule I
217     controlled substance unless:
218          (i) the individual who writes the prescription is licensed under Subsection (2); and
219          (ii) the prescribed controlled substance is to be used in research.
220          (f) Except when administered directly to an ultimate user by a licensed practitioner,
221     controlled substances are subject to the restrictions of this Subsection (7)(f).
222          (i) A prescription for a Schedule II substance may not be refilled.
223          (ii) A Schedule II controlled substance may not be filled in a quantity to exceed a
224     one-month's supply, as directed on the daily dosage rate of the prescriptions.
225          (iii) (A) [Except as provided in Subsection (7)(f)(iii)(B), a] A prescription for a
226     Schedule II or Schedule III controlled substance that is an opiate and that is issued for an acute
227     condition shall be completely or partially filled in a quantity not to exceed a seven-day supply
228     as directed on the daily dosage rate of the prescription.
229          [(B) Subsection (7)(f)(iii)(A) does not apply to a prescription issued for a surgery when
230     the practitioner determined that a quantity exceeding seven days is needed, in which case the
231     practitioner may prescribe up to a 30-day supply, with a partial fill at the discretion of the
232     practitioner.]
233          [(C)] (B) Subsection (7)(f)(iii)(A) does not apply to prescriptions issued for complex or
234     chronic conditions which are documented as being complex or chronic in the medical record.
235          [(D)] (C) A pharmacist is not required to verify that a prescription is in compliance
236     with Subsection (7)(f)(iii).
237          (iv) A Schedule III or IV controlled substance may be filled only within six months of
238     issuance, and may not be refilled more than six months after the date of its original issuance or
239     be refilled more than five times after the date of the prescription unless renewed by the
240     practitioner.
241          (v) All other controlled substances in Schedule V may be refilled as the prescriber's
242     prescription directs, but they may not be refilled one year after the date the prescription was
243     issued unless renewed by the practitioner.
244          (vi) Any prescription for a Schedule II substance may not be dispensed if it is not

245     presented to a pharmacist for dispensing by a pharmacist or a pharmacy intern within 30 days
246     after the date the prescription was issued, or 30 days after the dispensing date, if that date is
247     specified separately from the date of issue.
248          (vii) A practitioner may issue more than one prescription at the same time for the same
249     Schedule II controlled substance, but only under the following conditions:
250          (A) no more than three prescriptions for the same Schedule II controlled substance may
251     be issued at the same time;
252          (B) no one prescription may exceed a 30-day supply; and
253          (C) a second or third prescription shall include the date of issuance and the date for
254     dispensing.
255          (g) (i) Beginning January 1, 2022, each prescription issued for a controlled substance
256     shall be transmitted electronically as an electronic prescription unless the prescription is:
257          (A) for a patient residing in an assisted living facility as that term is defined in Section
258     26-21-2, a long-term care facility as that term is defined in Section 58-31b-102, or a
259     correctional facility as that term is defined in Section 64-13-1;
260          (B) issued by a veterinarian licensed under Title 58, Chapter 28, Veterinary Practice
261     Act;
262          (C) dispensed by a Department of Veterans Affairs pharmacy;
263          (D) issued during a temporary technical or electronic failure at the practitioner's or
264     pharmacy's location; or
265          (E) issued in an emergency situation.
266          (ii) The division, in collaboration with the appropriate boards that govern the licensure
267     of the licensees who are authorized by the division to prescribe or to dispense controlled
268     substances, shall make rules in accordance with Title 63G, Chapter 3, Utah Administrative
269     Rulemaking Act to:
270          (A) require that controlled substances prescribed or dispensed under Subsection
271     (7)(g)(i)(D) indicate on the prescription that the prescribing practitioner or the [pharamacy]
272     pharmacy is experiencing a technical difficulty or an electronic failure;
273          (B) define an emergency situation for purposes of Subsection (7)(g)(i)(E);
274          (C) establish additional exemptions to the electronic prescription requirements
275     established in this Subsection (7)(g);

276          (D) establish guidelines under which a prescribing practitioner or a pharmacy may
277     obtain an extension of up to two additional years to comply with Subsection (7)(g)(i);
278          (E) establish a protocol to follow if the pharmacy that receives the electronic
279     prescription is not able to fill the prescription; and
280          (F) establish requirements that comply with federal laws and regulations for software
281     used to issue and dispense electronic prescriptions.
282          (h) An order for a controlled substance in Schedules II through V for use by an
283     inpatient or an outpatient of a licensed hospital is exempt from all requirements of this
284     Subsection (7) if the order is:
285          (i) issued or made by a prescribing practitioner who holds an unrestricted registration
286     with the federal Drug Enforcement Administration, and an active Utah controlled substance
287     license in good standing issued by the division under this section, or a medical resident who is
288     exempted from licensure under Subsection 58-1-307(1)(c);
289          (ii) authorized by the prescribing practitioner treating the patient and the prescribing
290     practitioner designates the quantity ordered;
291          (iii) entered upon the record of the patient, the record is signed by the prescriber
292     affirming the prescriber's authorization of the order within 48 hours after filling or
293     administering the order, and the patient's record reflects the quantity actually administered; and
294          (iv) filled and dispensed by a pharmacist practicing the pharmacist's profession within
295     the physical structure of the hospital, or the order is taken from a supply lawfully maintained by
296     the hospital and the amount taken from the supply is administered directly to the patient
297     authorized to receive it.
298          (i) A practitioner licensed under this chapter may not prescribe, administer, or dispense
299     a controlled substance to a child, without first obtaining the consent required in Section
300     78B-3-406 of a parent, guardian, or person standing in loco parentis of the child except in cases
301     of an emergency. For purposes of Subsection (7)(i), "child" has the same meaning as defined
302     in Section 78A-6-105, and "emergency" means any physical condition requiring the
303     administration of a controlled substance for immediate relief of pain or suffering.
304          (j) A practitioner licensed under this chapter may not prescribe or administer dosages
305     of a controlled substance in excess of medically recognized quantities necessary to treat the
306     ailment, malady, or condition of the ultimate user.

307          (k) A practitioner licensed under this chapter may not prescribe, administer, or
308     dispense any controlled substance to another person knowing that the other person is using a
309     false name, address, or other personal information for the purpose of securing the controlled
310     substance.
311          (l) A person who is licensed under this chapter to manufacture, distribute, or dispense a
312     controlled substance may not manufacture, distribute, or dispense a controlled substance to
313     another licensee or any other authorized person not authorized by this license.
314          (m) A person licensed under this chapter may not omit, remove, alter, or obliterate a
315     symbol required by this chapter or by a rule issued under this chapter.
316          (n) A person licensed under this chapter may not refuse or fail to make, keep, or
317     furnish any record notification, order form, statement, invoice, or information required under
318     this chapter.
319          (o) A person licensed under this chapter may not refuse entry into any premises for
320     inspection as authorized by this chapter.
321          (p) A person licensed under this chapter may not furnish false or fraudulent material
322     information in any application, report, or other document required to be kept by this chapter or
323     willfully make any false statement in any prescription, order, report, or record required by this
324     chapter.
325          (8) (a) (i) Any person licensed under this chapter who is found by the division to have
326     violated any of the provisions of Subsections (7)(k) through (o) or Subsection (10) is subject to
327     a penalty not to exceed $5,000. The division shall determine the procedure for adjudication of
328     any violations in accordance with Sections 58-1-106 and 58-1-108.
329          (ii) The division shall deposit all penalties collected under Subsection (8)(a)(i) [in] into
330     the General Fund as a dedicated credit to be used by the division under Subsection
331     58-37f-502(1).
332          (iii) The director may collect a penalty that is not paid by:
333          (A) referring the matter to a collection agency; or
334          (B) bringing an action in the district court of the county where the person against
335     whom the penalty is imposed resides or in the county where the office of the director is located.
336          (iv) A county attorney or the attorney general of the state shall provide legal assistance
337     and advice to the director in an action to collect a penalty.

338          (v) A court shall award reasonable attorney fees and costs to the prevailing party in an
339     action brought by the division to collect a penalty.
340          (b) Any person who knowingly and intentionally violates Subsections (7)(h) through (j)
341     or Subsection (10) is:
342          (i) upon first conviction, guilty of a class B misdemeanor;
343          (ii) upon second conviction, guilty of a class A misdemeanor; and
344          (iii) on third or subsequent conviction, guilty of a third degree felony.
345          (c) Any person who knowingly and intentionally violates Subsections (7)(k) through
346     (o) shall upon conviction be guilty of a third degree felony.
347          (9) Any information communicated to any licensed practitioner in an attempt to
348     unlawfully procure, or to procure the administration of, a controlled substance is not considered
349     to be a privileged communication.
350          (10) A person holding a valid license under this chapter who is engaged in medical
351     research may produce, possess, administer, prescribe, or dispense a controlled substance for
352     research purposes as licensed under Subsection (2) but may not otherwise prescribe or dispense
353     a controlled substance listed in Section 58-37-4.2.
353a          Ĥ→ (11) (a) As used in this Subsection (11):
353b          (i) "High risk prescription" means a prescription for an opiate or a benzodiazepine that
353c     is written to continue for longer than 30 consecutive days.
353d          (ii) "Database" means the controlled substance database created in Section 58-37f-201.
353e          (b) A practitioner who issues a high risk prescription to a patient shall, before issuing
353f     the high risk prescription to the patient, verify in the database that the patient does not have a
353g     high risk prescription from a different practitioner that is currently active.
353h          (c) If the database shows that the patient has received a high risk prescription that is
353i     currently active from a different practitioner, the practitioner may not issue a high risk
353j     prescription to the patient unless the practitioner:
353k          (i) contacts and consults with each practitioner who issued a high risk prescription that
353l     is currently active to the patient;
353m          (ii) documents in the patient's medical record that the practitioner made contact with
353n     each practitioner in accordance with Subsection (11)(c)(i); and
353o          (iii) documents in the patient's medical record the reason why the practitioner believes
353p     that the patient needs multiple high risk prescriptions from different practitioners.
353q          (d) A practitioner shall satisfy the requirement described in Subsection (11)(c) in a
353r     timely manner, which may be after the practitioner issues the high risk prescription to
353s     ☆the patient.
353t          Ŝ→ [
(e) Failure to comply with the requirements in this Subsection (11) is unprofessional
353u     conduct.
] ←Ŝ